Cargando…

Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients

BACKGROUND: Psoriatic arthritis is a chronic inflammatory arthropathy that affects 14%-30% of patients with skin and/or nail psoriasis, leading to severe physical limitations and disability. It has been included in the group of spondyloarthropathy with which it shares clinical, radiologic, and sero-...

Descripción completa

Detalles Bibliográficos
Autores principales: Peluso, Rosario, Caso, Francesco, Tasso, Marco, Ambrosino, Pasquale, Di Minno, Matteo Nicola Dario, Lupoli, Roberta, Criscuolo, Livio, Caso, Paolo, Ursini, Francesco, Del Puente, Antonio, Scarpa, Raffaele, Costa, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691775/
https://www.ncbi.nlm.nih.gov/pubmed/29542417
http://dx.doi.org/10.2174/1574887113666180314105511
_version_ 1783443447427891200
author Peluso, Rosario
Caso, Francesco
Tasso, Marco
Ambrosino, Pasquale
Di Minno, Matteo Nicola Dario
Lupoli, Roberta
Criscuolo, Livio
Caso, Paolo
Ursini, Francesco
Del Puente, Antonio
Scarpa, Raffaele
Costa, Luisa
author_facet Peluso, Rosario
Caso, Francesco
Tasso, Marco
Ambrosino, Pasquale
Di Minno, Matteo Nicola Dario
Lupoli, Roberta
Criscuolo, Livio
Caso, Paolo
Ursini, Francesco
Del Puente, Antonio
Scarpa, Raffaele
Costa, Luisa
author_sort Peluso, Rosario
collection PubMed
description BACKGROUND: Psoriatic arthritis is a chronic inflammatory arthropathy that affects 14%-30% of patients with skin and/or nail psoriasis, leading to severe physical limitations and disability. It has been included in the group of spondyloarthropathy with which it shares clinical, radiologic, and sero-logic features in addition to familial and genetic relationship. Beyond skin and joint involvement, psoriat-ic arthritis is characterized by a high prevalence of extra-articular manifestation and comorbidities, such as autoimmune, infectious and neoplastic diseases. In particular, an increased risk of cardiovascular comorbidity has been observed in psoriatic arthritis patients. METHODS: A systematic search was performed in the electronic databases (PubMed, Web of Science, Scopus, EMBASE) up until January 2017. Studies were included if they contained data on CV disease and/or risk factors in PsA and each article was then reviewed for quality and clinical relevance. After completing the literature search all screened literature was summarized and discussed in our study group (CaRDDs study group). All literature and comments were included in the systematic review. RESULTS: The initial search produced 278 abstracts, which were narrowed to 83 potentially relevant arti-cles by preliminary review of the titles and by excluding review articles and case report (n = 195). Thirty articles were deemed ineligible after examining the abstracts. Full texts of the remaining 53 articles were retrieved. The majority of articles excluded were due to only providing data on patients with psoriasis or due to being not relevant to the CV risk in PsA. In the end, 32 articles were deemed eligible for this re-view. CONCLUSION: Psoriatic arthritis appeared significantly associated with subclinical atherosclerosis and en-dothelial dysfunction and, in turn, with an increased cardiovascular risk. Thus, patients with psoriatic ar-thritis may benefit from a periodic assessment of surrogate markers of cardiovascular risk. This could help to establish more specific cardiovascular prevention strategies for these patients
format Online
Article
Text
id pubmed-6691775
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-66917752019-09-05 Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients Peluso, Rosario Caso, Francesco Tasso, Marco Ambrosino, Pasquale Di Minno, Matteo Nicola Dario Lupoli, Roberta Criscuolo, Livio Caso, Paolo Ursini, Francesco Del Puente, Antonio Scarpa, Raffaele Costa, Luisa Rev Recent Clin Trials Article BACKGROUND: Psoriatic arthritis is a chronic inflammatory arthropathy that affects 14%-30% of patients with skin and/or nail psoriasis, leading to severe physical limitations and disability. It has been included in the group of spondyloarthropathy with which it shares clinical, radiologic, and sero-logic features in addition to familial and genetic relationship. Beyond skin and joint involvement, psoriat-ic arthritis is characterized by a high prevalence of extra-articular manifestation and comorbidities, such as autoimmune, infectious and neoplastic diseases. In particular, an increased risk of cardiovascular comorbidity has been observed in psoriatic arthritis patients. METHODS: A systematic search was performed in the electronic databases (PubMed, Web of Science, Scopus, EMBASE) up until January 2017. Studies were included if they contained data on CV disease and/or risk factors in PsA and each article was then reviewed for quality and clinical relevance. After completing the literature search all screened literature was summarized and discussed in our study group (CaRDDs study group). All literature and comments were included in the systematic review. RESULTS: The initial search produced 278 abstracts, which were narrowed to 83 potentially relevant arti-cles by preliminary review of the titles and by excluding review articles and case report (n = 195). Thirty articles were deemed ineligible after examining the abstracts. Full texts of the remaining 53 articles were retrieved. The majority of articles excluded were due to only providing data on patients with psoriasis or due to being not relevant to the CV risk in PsA. In the end, 32 articles were deemed eligible for this re-view. CONCLUSION: Psoriatic arthritis appeared significantly associated with subclinical atherosclerosis and en-dothelial dysfunction and, in turn, with an increased cardiovascular risk. Thus, patients with psoriatic ar-thritis may benefit from a periodic assessment of surrogate markers of cardiovascular risk. This could help to establish more specific cardiovascular prevention strategies for these patients Bentham Science Publishers 2018-09 2018-09 /pmc/articles/PMC6691775/ /pubmed/29542417 http://dx.doi.org/10.2174/1574887113666180314105511 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Peluso, Rosario
Caso, Francesco
Tasso, Marco
Ambrosino, Pasquale
Di Minno, Matteo Nicola Dario
Lupoli, Roberta
Criscuolo, Livio
Caso, Paolo
Ursini, Francesco
Del Puente, Antonio
Scarpa, Raffaele
Costa, Luisa
Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
title Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
title_full Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
title_fullStr Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
title_full_unstemmed Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
title_short Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
title_sort cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691775/
https://www.ncbi.nlm.nih.gov/pubmed/29542417
http://dx.doi.org/10.2174/1574887113666180314105511
work_keys_str_mv AT pelusorosario cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT casofrancesco cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT tassomarco cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT ambrosinopasquale cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT diminnomatteonicoladario cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT lupoliroberta cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT criscuololivio cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT casopaolo cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT ursinifrancesco cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT delpuenteantonio cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT scarparaffaele cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT costaluisa cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients
AT cardiovascularriskmarkersandmajoradversecardiovasculareventsinpsoriaticarthritispatients